GO:0032342 aldosterone biosynthetic process

The Gene Ontology term GO:0032342, aldosterone biosynthetic process, is defined as the chemical reactions and pathways resulting in the formation of aldosterone, a corticosteroid hormone produced by the zona glomerulosa of the adrenal cortex that regulates salt (sodium and potassium) and water balance. Aldosterone is the principal mineralocorticoid in humans, and its biosynthesis sits at the end of the renin-angiotensin-aldosterone system (RAAS), a hormonal cascade that adjusts renal sodium reabsorption and potassium excretion to maintain extracellular fluid volume and blood pressure. Because aldosterone production is tightly coupled to physiological demand, the enzymes and signaling molecules that execute GO:0032342 are of broad interest to endocrinologists, nephrologists and cardiovascular researchers. Dysregulation of aldosterone biosynthesis is clinically important. Primary aldosteronism, the most common form of secondary hypertension, is characterized by autonomous aldosterone production that is relatively independent of renin and is frequently caused by aldosterone-producing adenomas or bilateral adrenal hyperplasia. Secondary aldosteronism, by contrast, reflects excessive stimulation of the RAAS by conditions such as renal artery stenosis or heart failure. In both settings, the molecular steps that constitute GO:0032342 determine how much aldosterone is made and whether its production can be suppressed. For researchers, GO:0032342 provides a structured framework for interpreting transcriptomic, proteomic and functional data from adrenal cells and adrenal tumors. The term encompasses cholesterol mobilization, steroidogenic enzyme action, mitochondrial electron transfer and the terminal conversion of precursors into aldosterone, and it is therefore a useful annotation target when studying steroidogenic cell models, CRISPR-engineered adrenal lines and patient-derived adrenal tissue.

GO:0032342 aldosterone biosynthetic process is the biological process comprising the chemical reactions and pathways that result in the formation of aldosterone, a corticosteroid hormone produced by the zona glomerulosa of the adrenal cortex that regulates salt (sodium and potassium) and water balance. In practical terms, the term covers the steroidogenic sequence that converts cholesterol into aldosterone within adrenal glomerulosa cells, including the mitochondrial and endoplasmic reticulum enzyme reactions that generate the mineralocorticoid end product.

GO:0032342 is important because aldosterone is the final effector of the RAAS and a major determinant of sodium and potassium homeostasis, extracellular fluid volume and blood pressure. Abnormal aldosterone biosynthesis underlies primary aldosteronism, a common and potentially curable cause of hypertension, and contributes to secondary aldosteronism in conditions that activate the RAAS. Understanding the genes and signaling pathways that execute this process is therefore essential for diagnosis, for predicting treatment response and for developing targeted therapies that modulate aldosterone production.

The following genes and proteins are central to the aldosterone biosynthetic process and are frequently studied in adrenal cell and adrenal tumor models.

Aldosterone biosynthesis is regulated at multiple levels. Acutely, angiotensin II and potassium stimulate aldosterone production through calcium-dependent signaling in zona glomerulosa cells. Chronically, transcriptional control of CYP11B2 and related steroidogenic genes determines the capacity for aldosterone synthesis, and EGR1 has been shown to regulate oxidative stress and aldosterone production in adrenal cells and aldosterone-producing adenomas. Somatic mutations in ion channels and pumps such as KCNJ5, ATP1A1, ATP2B3, CACNA1D and CACNA1H can constitutively activate calcium signaling and drive autonomous aldosterone production in primary aldosteronism.

Primary aldosteronism is a common cause of secondary hypertension characterized by autonomous aldosterone production that is relatively independent of renin. It is frequently caused by aldosterone-producing adenomas or bilateral adrenal hyperplasia, and somatic mutations in KCNJ5, ATP1A1, ATP2B3, CACNA1D and CACNA1H contribute to its pathogenesis. The molecular basis of autonomous aldosterone biosynthesis is a major focus of endocrine research.

Secondary aldosteronism results from excessive activation of the RAAS rather than autonomous adrenal production, and occurs in conditions such as renal artery stenosis, heart failure and cirrhosis. In these settings, aldosterone biosynthesis is appropriately stimulated by angiotensin II and potassium but contributes to sodium retention and cardiovascular injury.

Aldosterone-producing adenomas are benign adrenal tumors that cause primary aldosteronism through ectopic or increased CYP11B2 expression and enhanced aldosterone biosynthesis. Research on these tumors has identified recurrent driver mutations and has linked oxidative stress and transcriptional regulators such as EGR1 to aldosterone production.

RNA sequencing and targeted expression assays can quantify CYP11B2 and other steroidogenic genes in adrenal cells and adrenal tumors, providing insight into the transcriptional programs that support aldosterone biosynthesis. Such profiling is often combined with mutation analysis to link genotype to aldosterone production.

Measuring aldosterone secretion in cell culture supernatants or patient samples allows researchers to test whether genetic perturbations alter the aldosterone biosynthetic process. These assays are commonly used with CRISPR-engineered adrenal cell models to establish causality.

Because angiotensin II, potassium and mutant ion channels act through calcium signaling, calcium imaging and electrophysiological recordings are used to study how depolarization and calcium entry stimulate aldosterone synthesis. Such methods help characterize the functional impact of KCNJ5, CACNA1D and CACNA1H variants.

Pooled CRISPR screens combined with bioinformatic analysis can identify genes that regulate aldosterone production or steroidogenic gene expression. These approaches are useful for discovering new modulators of GO:0032342 in adrenal cell models.

Researchers studying aldosterone biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in aldosterone production or is merely associated with adrenal disease. EDITGENE provides CRISPR-based cell model services that enable knockout, point-mutation, knock-in and overexpression studies in adrenal and other cell backgrounds, together with library screening and bioinformatics support for gene discovery and validation.

GO:0032342 aldosterone biosynthetic process provides a precise ontology framework for the steroidogenic reactions that generate aldosterone in the adrenal zona glomerulosa. Its clinical relevance is underscored by primary aldosteronism, a frequent cause of secondary hypertension driven by mutations in ion channels and pumps and by ectopic CYP11B2 expression. Continued research using CRISPR-engineered adrenal cell models and functional assays will clarify how candidate genes and regulatory factors such as EGR1 control aldosterone production.